Compound ID | 387
Class: Beta-lactam (penem)
| Spectrum of activity: | Gram-positive & Gram-negative | 
| Details of activity: | This was less active against MRSA and Pseudomonas than imipenem. Used against MRSA and CAP | 
| Institute where first reported: | Novartis, Switzerland | 
| Year first mentioned: | 1986 | 
| Highest developmental phase: | Preclinical | 
| Development status: | Inactive | 
| Reason Dropped: | The dosage tested in phase I was suggested to be administered 3 or 4 times daily. This inconvenience could be the reason of discontinuation (1). It also had a very short half life (2) Additionally, this appeared to be less potent than ritipenem | 
| Chemical structure(s): | |||||||||||
| 
 | 
 |